Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays

Clinical Chemistry

Volumn 44, Issue 7, 1998, Pages 1474-1480

  Kugler, Alan R ^a,c   Annesley, Thomas M ^b   Nordblom, Gerald D ^a   Koup, Jeffrey R ^a   Olson, Stephen C ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN;

ARTICLE; CROSS REACTION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MODEL; ULTRAVIOLET SPECTROSCOPY;

EID: 0031831704     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.7.1474     Document Type: Article

References (23)

1. Cloyd JC, Bosch DE, Sawchuk RJ. Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. Am J Hosp Pharm 1978;35:45-8.
2. Serrano EE, Wilder BJ. Intramuscular administration of diphenylhydantoin. Arch Neurol 1974;31:276-8.
3. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. JAMA 1983;249: 762-5.
4. Cloyd JC, Gumnit RJ, McLain W Jr. Status epilepticus: the role of intravenous phenytoin. JAMA 1980;244:1479-81.
5. Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990;40:(Suppl 2):9-13.
6. Leppik IE. Boucher BA, Wilder BJ, Murthy VS, Watridge C, Graves NM. et al. Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurology 1990;40:456-60.
7. Ramsay RE. Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde. Epilepsia 1989; 30(Suppl 2):S1-3.
8. Perrier D, Rapp R, Young B, Kostenbauder H, Cady W, Pancorbo S, Hackman J. Maintenance of therapeutic phenytoin plasma levels via intramuscular administration. Ann Intern Med 1976;85:318-21.
9. Wilder BJ, Serrano EE, Ramsay RE, Buchanan RA. A method for shifting from oral to intramuscular diphenylhydantoin administration. Clin Pharmacol Ther 1974;16:507-13.
10. Wilder BJ, Ramsay RE. Oral and intramuscular phenytoin. Clin Pharmacol Ther 1976;19(3):360-4.
11. Levine M, Chang T. Therapeutic drug monitoring of phenytoin: rationale and current status [Review]. Clin Pharmacokinet 1990; 19:341-58.
12. College of American Pathologists. Therapeutic drug monitoringgeneral, comprehensive survey, set Z-B. Northfield, IL: CAP, 1997:1-31.
13. Oellerich M. Enzyme immunoassays in clinical chemistry: present status and trends [Review]. J Clin Chem Clin Biochem 1980;18: 197-208.
14. Lu-Steffes M, Jolley M, Pittluck G, Pannas H, Olive D. Wang CHJ, et al. Fluorescence polarization immunoassays of phenytoin and phenobarbital [Abstract]. Clin Chem 1981;27:1093.
15. Cao Z, Stapp D, Linder MW, Miller JJ, Valdes R. Conversion of fosphenytoin to phenytoin in vitro [Abstract]. Clin Chem 1997;43: S219-20.
16. Cwik MJ, Liang M, Deyo K, Andrews C, Fischer J. Simultaneous rapid high-performance liquid Chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate. J Chromatogr B 1997;693:407-14.
17. Varia SA, Schuller S, Sloan KB, Stella VJ. Phenytoin prodrugs III: water soluble prodrugs for oral and/or parenteral use. J Pharm Sci 1984;73:1068-73.
18. Gerber N, Mays DC, Donn KH, Laddu A, Guthrie RM, Turlapaty P, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5, 5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol 1988;28: 1023-32.
19. Matheke ML, Valdes Jr R. Antibody specificity reduces interferences by endogenous digoxin-like immunoreactive factors. J Clin Immunoass 1989;12:115-21.
20. Miller JJ, Valdes Jr R. Methods for calculating crossreactivity in immunoassays. J. Clin Immunoass 1992;15:97-107.
21. Rainey PM, Rogers KE, Roberts WL. Metabolite and matrix interference in phenytoin immunoassays. Clin Chem 1996;42:1645-53.
22. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996;46:S3-7.
23. Pellock JM. Fosphenytoin use in children. Neurology 1996;46: S14-6.